Plain Language Summary {#Sec1}
======================

Serious infectious disease outbreaks and hospital-acquired infections are threats to human health. Effective vaccines and drug products are often not available, but antiseptic products for hand washing can help to control the spread of disease. Standard methods are used to test the effectiveness of hand hygiene products in the laboratory and on the hands of human volunteers.

We used a standard hand washing test method to find out whether two antiseptic products work against bacteria (*Escherichia coli*). The method was adapted to also test effectiveness against viruses (murine norovirus). The products tested were povidone-iodine scalp and skin cleanser, and chlorhexidine gluconate hand cleanser, which were compared to plain soft soap. After contamination of hands with the bacteria/virus, volunteers washed their hands for 15, 30 or 60 s, using 3 or 5 mL of product, in separate tests. Bacteria/viruses present on volunteers' hands were measured before and after hand washing. The antiseptic product had to remove significantly more bacteria/viruses than plain soap to be rated as effective.

Povidone-iodine cleanser and chlorhexidine gluconate cleanser were both more effective than plain soap at removing bacteria from volunteers' hands. Povidone-iodine cleanser was more effective than plain soap at removing viruses, except when using 3 mL product for 15 s. Chlorhexidine gluconate cleanser was less effective than plain soap at removing viruses in all tests. The adapted test method using murine norovirus worked well, giving consistent results for each product, and may be suitable for future testing of antiseptic products against viruses.

Introduction {#Sec2}
============

The importance of hand hygiene in health care and community settings is undoubted, with numerous studies demonstrating the association between proper hand hygiene and reductions in both rates of nosocomial infections \[[@CR1]--[@CR3]\] and rates of infectious illnesses in communities \[[@CR4]\]. Hand hygiene is also an infection control procedure that can be rapidly adopted by the public and healthcare workers in the case of emerging and re-emerging infectious diseases to limit the spread of viruses by breaking the transmission \[[@CR5], [@CR6]\].

Multiple hand hygiene agents are currently available including plain non-medicated soap, medicated hand washes with various active ingredients, and waterless or alcohol-based hand rubs. Although the use of alcohol-based hand rubs is convenient, the World Health Organization (WHO) recommends washing hands with soap and water when visibly dirty or visibly soiled with blood or other body fluids \[[@CR2]\]. It is recognized that some antiseptics and alcohol-based hand rubs are characterized by resistant bacteria and efficacy gaps \[[@CR1]--[@CR3]\]. In vitro suspension tests and human challenge trials help to demonstrate which hand hygiene agents are fit for purpose, but variations in methodology affect the measurement of efficacy \[[@CR7]\]. Ensuring that hand rub and hand wash products pass standardized antimicrobial activity tests helps to better understand and interpret efficacy results \[[@CR7]\].

In Europe, the most commonly used methods to test hand antiseptics are those of the European Committee for Standardization (CEN), while in the USA and Canada, the standards of ASTM International (formerly, the American Society for Testing and Materials) are used. The CEN has adopted a hierarchical, systematic approach of product testing. In this concept, European Standards EN1276 and EN14476 are established initial in vitro methods to determine the bactericidal and virucidal efficacy of antiseptics and disinfectants \[[@CR8], [@CR9]\]. The next step in the CEN testing scheme is European standard EN1499 (for hand washes) and EN1500 (for hand rubs), each Phase 2/Step 2 hand simulation studies where the hands of volunteers are artificially contaminated with *E. coli* and the test product is compared against a reference procedure in a crossover design \[[@CR10], [@CR11]\]. To fill in gaps within the in vitro CEN testing, modified vaccinia virus Ankara (MVA) was introduced in 2015 as a reference virus for the claim of virucidal activity against enveloped viruses for hygienic hand rub and hand wash products \[[@CR9], [@CR12], [@CR13]\]. However, it has not been possible to develop a Phase 2/Step 2 test for enveloped viruses due to the lack of availability of a safe enveloped virus that can be ethically used in testing on volunteers' hands, and there is currently no standard in vivo test method for viruses. To fill this gap, a hand simulation test has recently been considered that uses murine norovirus (MNV), a non-pathogenic (biosafety level 1) non-enveloped virus, which is more resilient to antiseptics than enveloped viruses, as a model test organism.

Povidone-iodine (PVP-I) and chlorhexidine gluconate (CHG) are broad-spectrum antimicrobials that have been used in infection control and prevention for more than 60 years. PVP-I has well-established general antimicrobial activity, particularly in relation to resistant organisms \[[@CR2]\], demonstrating in vitro activity against Gram-positive, Gram-negative and some spore-forming bacteria (*Clostridia*,*Bacillus* spp.) and mycobacteria \[[@CR2], [@CR14]--[@CR18]\] and a wide range of enveloped and non-enveloped viruses \[[@CR12], [@CR13], [@CR19]--[@CR22]\]. In contrast, CHG has good in vitro activity against Gram-positive bacteria and enveloped viruses, less activity against Gram-negative bacteria and non-enveloped viruses, and minimal activity against mycobacteria \[[@CR22]--[@CR28]\]. CHG resistance is a concern and has been detected in isolates of *Enterobacter* spp., *Pseudomonas* spp., *Proteus* spp., *Providencia* spp. and *Enterococcus* spp \[[@CR29]\]. In vivo studies using artificial fingertip contamination have previously shown PVP-I and 70% ethyl alcohol to be more effective than plain soap in removing methicillin-resistant *Staphylococcus aureus* (MRSA), *Acinetobacter baumannii* and *E. coli* from volunteers' hands, while CHG was only significantly more effective than plain soap at removing *E. coli* \[[@CR30]--[@CR33]\]. In vivo virucidal studies are generally lacking; however, in a modified finger pad test based on the ASTM E 1838 \[[@CR34]\] using MNV, PVP-I was shown to have superior efficacy to three alcohol-based hand rubs while 4% CHG and 1% triclosan showed no activity \[[@CR35]\].

We undertook two hand hygiene in vivo clinical simulation studies to investigate the bactericidal and virucidal efficacy of PVP-I 7.5% scalp and skin cleanser and CHG 4% hand cleanser versus the reference hand wash (soft soap) on healthy volunteers' hands. Both studies followed European standard EN1499 as a function of employed soap volume and hand washing time. The virucidal study was performed in an exploratory manner using murine norovirus (MNV) as model test virus.

Methods {#Sec3}
=======

Study Design {#Sec4}
------------

Each study was randomized, controlled, open label, crossover and exploratory in design. The bactericidal study was conducted at the laboratories of Hygiene Nord, Greifswald, Germany, from 1 September 2016 to 19 January 2017. The virucidal study was conducted at the laboratories of Labor Prof. Gisela Enders MVZ GbR, Stuttgart, Germany, from 14 September 2016 to 12 December 2016. Hand hygiene tests were performed on the hands of healthy volunteers simulating practical use according to the methods described in European Standard EN1499:2013 (hygienic hand wash test method for bacteria), which were adapted and used in an exploratory manner to assess the virucidal activity of the hand cleansers. All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the studies. Ethics approval was not required as EN studies of this type are covered by a waiver by the Federal Institute for Drugs and Medical Devices (BfArM) in place in Germany.

Test Organisms {#Sec5}
--------------

*Escherichia coli* K 12, NCTC 10538, was used as the test organism in the bactericidal study. *E.* *coli* was chosen, as specified by EN1499, since this is the organism that the EN1499 method is validated for in every respect, including volunteers' safety. The contamination fluid used for each test contained between 2.19 × 10^8^ and 5.10 × 10^8^ colony-forming units (cfu)/mL *E. coli*.

MNV Berlin, strain S99 was used as the test organism in the virucidal study. MNV was chosen as the test virus due to the absence of pathogenicity for humans. The host cells used for virus cultivation were RAW 264.7 (murine macrophage cell line). The titers of MNV present in the test suspensions ranged from 7.67 to 8.83 log~10~ tissue culture infectious dose 50% (TCID~50~)/mL.

Hand-Cleansing Agents {#Sec6}
---------------------

The test hand cleansing agents in both studies were PVP-I 7.5% w/v scalp and skin cleanser (Mundipharma Pharmaceuticals, Nicosia, Cyprus) and chlorhexidine gluconate 4% w/v hand cleanser (Mölnlycke Health Care US, Norcross, GA, USA). The reference hand wash procedure used plain soft soap (Sapo kalinus, Pharm. Eur.) 20% w/v. Hand cleansing agents were tested undiluted.

Healthy Volunteers {#Sec7}
------------------

A total of 15 healthy adult volunteers were screened and enrolled in each study. All volunteers were in general good health with normal skin (free of dermatoses, cuts, lesions, hangnails and other skin disorders), short fingernails (\< 2 mm in length), no history of skin disease and had not used oral or topical antibiotics within the previous 2 weeks. All volunteers abstained from using antimicrobial products for 7 days prior to testing and during the whole study.

Experimental Design {#Sec8}
-------------------

The same study design based on EN1499 was used for both studies, with adaptations for viral testing. Randomization to treatment sequence was performed using a Latin Square design. Each volunteer tested each hand cleansing agent and the reference soft soap at 3 and 5 mL volumes, with each volume tested after washing for 15, 30 and 60 s. Testing was repeated weekly, with volunteers testing all three hand cleansing agents at one volume and application time on each of six test days. At the end of the whole series, every volunteer had tested each product, volume and application time once.

Bactericidal Test Method {#Sec9}
------------------------

The bactericidal test method is summarized in Fig. [1](#Fig1){ref-type="fig"}. Testing was performed at 20 ± 1 °C. Hands were prepared by washing for 60 s with 5 mL of soft soap to remove transient bacteria and dried with paper towels. Hands were immersed in the contamination fluid for 5 s and then allowed to dry in the air for 3 min, avoiding the formation of droplets. Pre-washing samples were obtained by rubbing the fingertips and thumb tips on the base of a Petri dish containing 10 mL tryptic soy broth (TSB, without neutralizer) for 60 s. A separate dish was used for each hand. Dilutions of 10^−3^ and 10^−4^ were prepared in TSB and 0.1 mL of each dilution was plated on the surface of a tryptic soy agar (TSA) plate and incubated at 36 °C ± 1 °C for 24 h.Fig. 1Bactericidal hygienic hand wash test method and requirements (based on EN1499)

Volunteers then washed their wetted hands with test product or reference soft soap following the standard hand wash procedure specified in EN1499. According to EN1499, the standard hand wash procedure was completed by a 10-s rinse of the hands under cold running tap water. Volunteers held their hands with fingertips pointing upwards until post-washing samples were taken by rubbing the fingertips and thumb tips on the base of a Petri dish containing 10 mL of TSB (with neutralizer) for 60 s. A separate dish was used for each hand. Amounts of 1.0 and 0.1 mL of the undiluted sampling fluid and 0.1 mL of a 10^−1^ dilution were prepared in TSB, plated on the surface of TSA plates and incubated at 36 ± 1 °C for 24 h. Neutralizer XXXII (4% Tween80 + 3% saponin + 2% histidine + 0.4% lecithin + 0.5% SDS) was used for CHG and Neutralizer XLIV + 2% sodium thiosulfate (6% Tween80 + 0.2% histidine + 0.6% lecithin +2% sodium-thiosulfate + 0.2% peptone + 1.7% sodium chloride + 1.8% di-sodium hydrogen phosphate + 0.3% potassium dihydrogen phosphate) was used for PVP-I.

The number of test organisms released from the fingertips into sampling fluids was assessed before and after the hygienic hand wash and the number of viable bacteria were expressed as cfu per mL. The bactericidal activity was determined by the difference of the mean log pre-washing value minus the mean log post-washing value. This difference was given as a reduction factor.

Virucidal Test Method {#Sec10}
---------------------

The virucidal test method is summarized in Fig. [2](#Fig2){ref-type="fig"}. Testing was performed at 20.0 ± 0.5 °C. To remove transient viruses, 5 mL of diluted soft soap was applied to the cupped hands of volunteers and was rubbed in for 60 s before rinsing with tap water and drying with paper towels for 30 s. Hands were inoculated with a low concentration suspension of MNV. Volunteers were asked to cup their hands carefully, 250 µL of inoculate was slowly pipetted into the palms, then volunteers gently rubbed their hands together until all surfaces of the hands were coated with the inoculate. Finally, volunteers rotated their hands in the air for 60 s to allow the inoculate to dry. Pre-washing samples were obtained by rubbing the fingertips of the inoculated hands on the base of a Petri dish containing 5 mL Dulbeccos Minimum Essential Medium for 60 s, followed by drying hands in the air for 60 s. Volunteers then washed their hands with the test product or reference soft soap following the standard hand wash procedure specified in EN1499 before post-washing samples were obtained using the same methods used pre-washing. The Petri dishes were incubated at 37 ± 1 °C under 5% CO~2~.Fig. 2Virucidal hygienic hand wash test method and requirements (as adapted From EN1499)

The number of test organisms released from the fingertips into sampling fluids was assessed before and after the hygienic hand wash, and virus titers were expressed TCID~50~/mL. The virucidal activity was determined by the difference of the logarithmic titer of the pre-washing sample minus the logarithmic titre of the post-washing sample (Δlog~10~ TCID~50~/mL). This difference was given as a reduction factor.

Statistical Analysis {#Sec11}
--------------------

The primary endpoint for each study was the mean log~10~ reduction factor of the test organism after the hand wash with each product at each pre-defined application time (15, 30 or 60 s) and product volume (3 or 5 mL). For testing the data obtained in a Latin-square design experiment (where the results of more than one test treatment are compared), the statistical analysis methods proposed in EN1499 \[comparison of test treatments with a reference treatment (5 mL soft soap for 60 s) in a pairwise manner using a Wilcoxon--Wilcox multiple comparisons test\] were applied, although used in an exploratory manner for the virucidal study. The pass criterion for EN1499 was a significance of the observed differences between the test and reference of *p* ≤ 0.01. The two test treatments were also compared using the same method in an exploratory manner. The sample size (*n*  = 15) was based on the recommendation given in EN1499.

Results {#Sec12}
=======

Bactericidal Testing {#Sec13}
--------------------

The reference hand wash procedure with 5 mL soft soap for 60 s resulted in a mean log~10~ reduction of *E. coli* of 2.91. The mean log~10~ reductions achieved with the test products PVP-I and CHG were statistically significantly greater (*p* ≤ 0.01) than the reduction achieved with the reference soft soap for all product volumes and contact times (Table [1](#Tab1){ref-type="table"}). There was no statistically significant difference in mean log~10~ reduction factors between the different hand washing times using soft soap at either volume (3 or 5 mL). A small trend towards a greater bacterial reduction with longer washing times was observed for both test products (except 3 mL CHG; Table [1](#Tab1){ref-type="table"}). An exploratory comparison of PVP-I and CHG showed that there was no statistically significant difference between the two test products for all volumes and time points (*p* \> 0.01) (Table [1](#Tab1){ref-type="table"}).Table 1Results of practical hand wash test with *Escherichia coli* according to EN1499Test parameterReference soft soapPVP-ICHGProduct volumeContact time (s)Pre-valuePost-valueLog~10~ reduction^a^Pre-valuePost valueLog~10~ reduction^a^Pre-valuePost-valueLog~10~ reduction^a^3 mL156.053.242.805.991.904.09^b^6.030.815.22^b^305.933.102.835.941.454.48^b^5.950.865.09^b^605.822.962.865.911.124.97^b^6.000.865.14^b^5 mL156.022.903.115.931.714.22^b^6.001.874.12^b^305.893.142.755.811.494.32^b^5.971.644.33^b^605.963.052.915.940.675.27^b^5.861.234.63^b^Each value represents the mean from 30 samples (left and right hands of 15 volunteers)*CHG* chlorhexidine gluconate 4% hand cleanser, *PVP-I* povidone-iodine 7.5% hand cleanser^a^Mean log~10~ reduction of post-washing versus pre-washing samples^b^Demonstrated a significant difference versus the reference soft soap at the *p* = 0.01 level (one-sided), denoting that the test product passes the EN1499 test. The reference procedure with soft soap always used 5 mL soap for 60 s contact time per EN1499 standard

Virucidal Testing {#Sec14}
-----------------

The experimental design using EN1499 is applicable to viral testing with MNV as discriminatory and reproducible results were generated (Table [2](#Tab2){ref-type="table"}).Table 2Results of practical hand wash test with murine norovirus according to EN1499Test parameterReference soft soapPVP-ICHGProduct volumeContact time (s)Pre-valuePost-valueLog~10~ reduction^a^Pre-valuePost valueLog~10~ reduction^a^Pre-valuePost-valueLog~10~ reduction^a^3 mL155.464.221.245.664.091.575.524.620.90306.334.711.626.414.282.13^b^6.044.871.18606.374.921.456.193.622.57^b^6.274.921.345 mL156.284.881.416.614.621.99^b^6.585.301.28305.994.641.356.054.281.78^b^5.904.821.08606.274.831.446.003.812.19^b^6.124.831.28Each value represents the mean from 30 samples (left and right hands of 15 volunteers)*CHG* chlorhexidine gluconate 4% hand cleanser, *PVP-I* povidone-iodine 7.5% hand cleanser^a^Mean log~10~ reduction of post-washing versus pre-washing samples^b^Demonstrated a significant difference versus the reference soft soap at the *p* = 0.01 level (one-sided) in the modified EN1499 test

The reference hand wash procedure with 5 mL soft soap for 60 s resulted in a mean log~10~ reduction factor of 1.44. The mean log~10~ reduction factor achieved with PVP-I was significantly greater than the reduction achieved with the reference soft soap (*p* ≤ 0.01) across all tests, except for the application of 3 mL for 15 s, for which the reduction achieved was numerically but not statistically superior for PVP-I compared with the reference soft soap (Table [2](#Tab2){ref-type="table"}). In contrast, the mean log~10~ reduction factor with CHG was lower than for the reference soft soap across all tests, and a significant reduction for CHG compared with the reference soft soap was not achieved (Table [2](#Tab2){ref-type="table"}). A small trend towards a greater viral reduction with longer washing times was observed for both test products (except 5 mL CHG) and soft soap (Table [2](#Tab2){ref-type="table"}). An exploratory comparison of PVP-I and CHG showed that the mean log~10~ reduction factor achieved with PVP-I was significantly greater than that achieved with CHG (*p* ≤ 0.01) at both 3 and 5 mL and across all application times.

Safety and Validation {#Sec15}
---------------------

No adverse events were observed or reported during or after either study. Controls and validations in both studies conformed to EN1499 requirements.

Discussion {#Sec16}
==========

The results of our bactericidal study confirm the positive results with respect to efficacy of PVP-I and CHG versus plain soap against *E. coli* shown in previous fingertip contamination studies \[[@CR32], [@CR36]\]. However, PVP-I (7.5 or 10%) has been shown to achieve significantly higher removal rates than CHG 4% and plain soap against other bacteria, including *Staphylococcus aureus*, MRSA and *A. baumannii* \[[@CR30], [@CR31], [@CR33], [@CR36]\]. It should be noted that alcohol rubs have outperformed PVP-I and CHG in removing *E.* *coli* in some studies \[[@CR32], [@CR36], [@CR37]\].

The findings of our virucidal study are in agreement with the results of a previous study by Steinmann et al. \[[@CR35]\] that used MNV as a test organism in a modified finger pad test based on the ASTM E 1838 \[[@CR34]\], with modifications derived from the EN1500 \[[@CR11]\]. Steinmann et al. found that a PVP-I formulation with 0.75--0.81% available iodine performed better than three alcohol-based hand rubs, while 4% CHG and 1% triclosan hand washes were ineffective \[[@CR35]\]. An earlier fingertip test using feline calcivirus (a surrogate for norovirus) by Lages et al. also showed a significantly greater log~10~ reduction factor for 10% PVP-I antiseptic compared with two triclosan-containing soaps and five hand sanitizers after 30 s contact time \[[@CR38]\]. A recent review of in vitro and in vivo virucidal activity of ethanol concluded that 80% ethanol is highly effective against enveloped viruses, MNV and adenovirus type 5 are usually inactivated by 70--90% ethanol, while 95% ethanol is required to inactivate most other non-enveloped viruses \[[@CR39]\].

Based on the results of our studies and the in vivo studies discussed above, the antimicrobial efficacy of PVP-I appears consistently better than plain soap, whereas CHG performs worse than plain soap against viruses. The soap component of the CHG-containing cleanser should have mechanically reduced the viral count down to a similar level as the reference product, which may go beyond efficacy gaps. The bicationic character of the CHG molecule, that is responsible for adhesion to surfaces and retention of other components as observed in oral use \[[@CR40], [@CR41]\], may retain viruses too. This retention phenomenon is not only seen with viruses \[[@CR42]\] but also with some Gram-negative bacteria such as *A. baumannii* \[[@CR31]\]. It should be noted that, due to the established cumulative effect of CHG \[[@CR2], [@CR3]\], repeated use may result in greater activity than shown in single-use studies, although repeated use of CHG may also increase its known risk of development of resistance \[[@CR2], [@CR29], [@CR43]\]. In contrast, PVP-I demonstrates less persistent activity \[[@CR2], [@CR3]\], but is not associated with development of resistance \[[@CR44]\].

The method set-up of the EN1499 standard can be considered more robust than the ASTM E method, since it employs an internal standard (i.e., plain soft soap, 5 mL applied for 60 s) with defined success criteria, instead of measuring log reductions alone for pass criteria. Log reductions alone are subject to inherent variability in such complex biological systems as concentration of infected cells in the inoculate and the details of the individual hand wash procedure. The use of an internal standard also allows assessment of the biocidal power of the test product versus the purely mechanical/detergent-based removal of test organisms by non-medicated soft soap. Additionally, the EN1499 method has more power to demonstrate efficacy of the products tested due to the larger sample size (15 volunteers) compared with the ASTM E method and several previous fingertip bactericidal studies \[[@CR30], [@CR31], [@CR36]\], which include 5 volunteers. The hand wash procedure was standardized as much as possible in our study by following the CEN procedure (in the meanwhile adapted by WHO) closely, and shorter contact times of 15 and 30 s were included to more closely reflect real-life use \[[@CR45]--[@CR47]\]. The use of various volumes and exposure times also provided further validation of the internal reference used. We have shown for the first time in this study that the bacterial testing from EN1499 can be adapted to MNV-based viral testing and may be a good basis for further virucidal CEN standards, pending further validation as interlaboratory tests. It may be hypothesized that antiseptic products which are effective against non-enveloped viruses such as MNV will be effective against enveloped viruses such as Ebola (EBOV), severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses (SARS- and MERS-CoV), influenza and other emerging viruses; this is supported by the results of in vitro suspension tests with the modified vaccinia virus Ankara \[[@CR12], [@CR13]\].

An obvious limitation of our studies is the use of only a single test pathogen (*E.* *coli* and MNV). In vivo testing is necessarily restricted to medically safe organisms to minimize the risk to healthy human volunteers, and therefore *E. coli* (strain NCTC 10538) was chosen as the model pathogen for EN1499. ASTM E1174 \[[@CR48]\], the only other standard in vivo method employing the whole hands of human subjects, similarly suggests a single test organism (primarily, *Serratia marcescens*, or alternatively, *E. coli* strain ATCC 11229). ASTM E2276 \[[@CR49]\] allows for using a variety of medically relevant test species (*S. marcescens* ,*E. coli*,*A. baumannii*,*S. aureus*,*Staphylococcus epidermidis*,*Candida albicans*,*Aspergillus niger*), but confines testing to the finger pads rather than the whole hands and only assesses the simple removal of test organisms from the hands with no internal reference. In vitro data on potential efficacy gaps \[[@CR2]\] can be taken into consideration given the limitations of in vivo studies.

Another limitation of current in vivo standard test methods, including EN1499, is that they do not account for extrinsic factors such as protein load on soiled hands, residual activity (a notable characteristic of CHG \[[@CR2]\]) and how the product is used/applied by individuals \[[@CR3]\]. It should also be emphasized that the degree of reduction in microbial counts required to produce a meaningful drop in the hand-borne spread of nosocomial pathogens has yet to be quantified, and thus the clinical relevance of such in vivo test results remains unclear \[[@CR23], [@CR24]\]. Controlled clinical, observational and epidemiological studies are thus needed for more direct proof of clinical effectiveness, but are generally lacking, although PVP-I hand scrub has previously been shown to have superior efficacy to soap and water in a neonatal intensive care unit \[[@CR50]\].

Another important consideration in selection of hand hygiene agents, particularly in resource-poor countries, is cost and availability. Alcohol-based hand rub formulations proposed by the WHO have recently been shown to be effective against enveloped viruses including emerging Zika, EBOV, SARS-CoV and MERS-CoV in vitro \[[@CR51]\], and may be a more freely available and cost-effective alternative to medicated cleansers/antiseptics. Since hand rubs cannot properly cleanse soiled hands \[[@CR2]\], a phased approach as recommended by the National Institute for Health and Care Excellence \[[@CR52]\] may be an optimized approach to handle situations where increased hand hygiene is warranted.

Conclusion {#Sec17}
==========

In conclusion, in these simulated hand wash studies, PVP-I 7.5% scalp and skin cleanser passed the requirements of EN1499 (adapted for viruses) and showed significantly better efficacy against *E. coli* and MNV than the reference soft soap within 15 s using a 3-mL application (*E. coli*) or a 5-mL application (MNV). CHG 4% hand cleanser also passed the requirements of EN1499 against *E. coli* within 15 s using a 3-mL application, but was ineffective against MNV compared to hand washing with soft soap. Although the results have yet to be confirmed in clinical and epidemiological studies, these studies provide important public health information for the appropriate use of hand hygiene products.
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